New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2014
07:31 EDTARWRArrowhead completes enrollment of first cohort in phase 2a trial of ARC-520
Arrowhead Research Corporation announced that the first cohort of 8 patients has been fully enrolled and dosed in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus infection. The trial remains on schedule to meet the previously stated goal of completing dosing in the second quarter and releasing top line results in the third quarter. The Phase 2a study is planned to enroll up to 16 chronic HBV patients in two dose cohorts with patients receiving either ARC-520 or placebo in combination with entecavir. The study is designed to evaluate the depth and duration of hepatitis B surface antigen decline, among other measures, in response to a single dose of ARC-520.
News For ARWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 15, 2014
09:57 EDTARWRLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
06:06 EDTARWRArrowhead pullback since ARC-520 data an overreaction, says Piper Jaffray
Subscribe for More Information
October 14, 2014
14:54 EDTARWRQVT Financial raises passive stake in Arrowhead to 7.62% from 5.29%
Subscribe for More Information
October 13, 2014
07:12 EDTARWROligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information
October 10, 2014
12:11 EDTARWROptions with increasing implied volatility
Subscribe for More Information
October 9, 2014
11:00 EDTARWROptions with increasing implied volatility
Options with increasing implied volatility: ARWR PBR EXXI PWE GST GLNG WTW AFSI ETE VALE
10:00 EDTARWROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:38 EDTARWRArrowhead price target lowered to $12 from $24 at Piper Jaffray
Subscribe for More Information
08:33 EDTARWRArrowhead issues letter to shareholders regarding ARC-520
Subscribe for More Information
06:18 EDTARWRArrowhead downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded Arrowhead to Sector Perform citing low-end efficacy in the AASLD abstract. Price target lowered to $9.
05:50 EDTARWRStocks with implied volatility movement; ARWR TKMR
Stocks with implied volatility movement; Arrowhead (ARWR) 158, Tekmira (TKMR) 130 according to iVolatility.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use